Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)

Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is the anti-CD20 antibody rituximab. In recent years, new antibodie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Elias, Shlomo, Kahlon, Shira, Kotzur, Rebecca, Kaynan, Noah, Mandelboim, Ofer
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5980409/
https://ncbi.nlm.nih.gov/pubmed/29872553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1428158
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars